Two Human CB1-Blockade Trials Did Not Confirm the Alcohol Benefit Seen in Rodents
A review described favorable rodent drinking findings with CB1 blockade alongside two human rimonabant trials without significant efficacy results. The review’s proposed explanation for that gap was a hypothesis, not a positive clinical finding.
The clinical comparisons remained nonsignificant
Kunos summarized a relapse-prevention trial in 260 recently detoxified patients and a shorter study in 49 non-treatment-seeking heavy drinkers. Neither demonstrated a significant rimonabant benefit on the principal drinking comparisons discussed.
Numerical trends toward benefit should remain distinguishable from statistically demonstrated efficacy. They do not become confirmatory because they resemble animal findings.
Receptor occupancy was a proposed explanation
The review argued that limited receptor occupancy at the tested regimen might help explain the nulls, while higher exposure raised safety concerns. This was a mechanistic interpretation of why translation might have failed.
It did not establish that a higher dose would work safely or that occupancy alone caused the trial outcomes. Testing that explanation would require suitable additional evidence.
Do not turn translation uncertainty into treatment advice
These were studies of receptor blockade, rather than trials of marijuana as an alcohol treatment. The review did not establish a safe individualized regimen.
The useful distinction is between an experimental rationale, an observed human result and an explanation proposed afterward. Preserving all three prevents promising biology from being mistaken for confirmed clinical efficacy.
Related: Interpreting cannabis tolerance claims.
Research cited
Kunos G Alcoholism, clinical and experimental research · 2020 · 44(4):790 PMID 32056226 · DOI 10.1111/acer.14306. Interactions Between Alcohol and the Endocannabinoid System..
